Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | PDE4A | P27815 | 1/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | TNF | P01375 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | GALK1 | P51570 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | CASP7 | P55210 | 1/20 | 0.37 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.37 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10609598 | 0.78 | TNF (0.43) | KDM4EPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL29874726 | 0.75 | TDP1 (0.46) | KDM4ETNFALDH1A1GAALMNA | |
| SCHEMBL2586177 | 0.74 | TDP1 (0.40) | KDM4EPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL123411 | 0.74 | GAA (0.47) | KDM4EPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL29705981 | 0.74 | GAA (0.47) | KDM4EPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3971069 | 0.72 | KDM4E (0.44) | KDM4EPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL29614841 | 0.71 | CDK4 (0.45) | SMN1; SMN2HPGDMAPTALDH1A1KMT2A | |
| SCHEMBL321199 | 0.71 | CDK4 (0.45) | SMN1; SMN2HPGDMAPTALDH1A1KMT2A | |
| SCHEMBL3114855 | 0.71 | KDM4E (0.36) | KDM4EPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3114852 | 0.71 | KDM4E (0.36) | KDM4EPDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9623021-B2 | Nuclear receptor binding agents | GTX, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-9604931-B2 | Nuclear receptor binding agents | GTX, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20170014401-A1 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, INC. | 2017-01-19 | — | — | US | disclosed |
| US-9078888-B2 | Nuclear receptor binding agents | GTX, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-8889698-B2 | Compounds for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2014-11-18 | — | — | US | disclosed |
| US-20130150403-A1 | NUCLEAR RECEPTOR BINDING AGENTS | VA Long Beach Healthcare System (US) | 2013-06-13 | — | — | US | disclosed |
| EP-2566330-A1 | NUCLEAR RECEPTOR BINDING AGENTS | Gtx, Inc. (US) | 2013-03-13 | — | — | EP | disclosed |
| US-20120015905-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. | 2012-01-19 | — | — | US | disclosed |
| WO-2011140228-A1 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, INC. (US) | 2011-11-10 | — | — | WO | disclosed |
| US-20100267767-A1 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, INC. | 2010-10-21 | — | — | US | disclosed |
| US-20090030036-A1 | Nuclear receptor binding agents | GTX, INC. | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170014401-A1 | NUCLEAR RECEPTOR BINDING AGENTS | ESRRB, ESRRG, ESRRA | KDM4E 1789/4885PDE4A 1102/4885PDE4B 1495/4885 |
| US-20130150403-A1 | NUCLEAR RECEPTOR BINDING AGENTS | FABP3, NCOR1, NR3C2 | KDM4E 3187/4885PDE4A 492/4885PDE4B 827/4885 |
| US-20120015905-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, HDLBP, FABP3 | KDM4E 4404/4885PDE4A 1384/4885PDE4B 1783/4885 |
| US-20090030036-A1 | Nuclear receptor binding agents | NR0B1, NR2E3, NR0B2 | KDM4E 4528/4885PDE4A 2035/4885PDE4B 2262/4885 |
| US-20100267767-A1 | NUCLEAR RECEPTOR BINDING AGENTS | FABP1, FABP4, ADIPOR2 | KDM4E 3216/4885PDE4A 2551/4885PDE4B 3143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.